2.29 Time from Diagnosis to Treatment in AML and Real-World Data with Dr. Sherrie Aspinall

Plenary Session

English - December 27, 2019 17:56 - 1 hour - 64.3 MB - ★★★★★ - 732 ratings
Science Health & Fitness Medicine medicine oncology health policy Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: 2.28 Trastuzumab in Later Lines of Therapy for HER2+ Breast Cancer, Kaplan-Meier Curves, & Patreon

Next Episode: 2.30 Questions from a Medical Student & Epidemiology with Dr. Ellie Murray

This week we wonder incredulously how this abstract from ASH titled "Time from diagnosis to treatment does not affect outcome in intensively treated patients with newly diagnosed acute myeloid leukemia" was selected as one of the top abstracts from the conference. In the second half of the episode we interview Dr. Sherrie Aspinall of the Veterans Administration on how to use real-world data. Her new paper is titled "Use of targeted therapies for advanced renal cell carcinoma in the Veterans Health Administration".

Time from diagnosis to treatment in AML: https://ashpublications.org/blood/article-lookup/doi/10.1182/blood-2019-123717
Targeted therapies for advanced RCC: doi.org/10.1002/cam4.2531

Vinay's new book, Malignant: www.amazon.com/Malignant-Policy-…cer/dp/1421437635

Back us on Patreon! www.patreon.com/plenarysession